Bismuth Subsalicylate

Bismuth Subsalicylate is the active ingredient in Pepto-Bismol and inhibits prostaglandin G/H Synthase 1/2.Target: OthersBismuth Subsalicylate reduces inflammation/irritation of stomach and intestinal lining through inhibition of prostaglandin G/H Synthase 1/2 [1]. Bismuth Subsalicylate is the active ingredient in Pepto-Bismol, an anti-diarrhea medication and antacid. In the gastrointestinal tract, Bismuth Subsalicylate is converted to salicylic acid and insoluble bismuth salts [2]. Bismuth subsalicylate treatment for 8 weeks is safe and well tolerated. This regimen appears to be efficacious for the treatment of microscopic colitis and is worthy of further study in a controlled trial [3].

Signaling Pathways >> Immunology/Inflammation >> PGE synthase

Research Areas >> Neurological Disease

[1]. Sox, T.E. and C.A. Olson, Binding and killing of bacteria by bismuth subsalicylate. Antimicrob Agents Chemother, 1989. 33(12): p. 2075-82.

[2]. Bierer, D.W., Bismuth subsalicylate: history, chemistry, and safety. Rev Infect Dis, 1990. 12 Suppl 1: p. S3-8.

[3]. Fine, K.D. and E.L. Lee, Efficacy of open-label bismuth subsalicylate for the treatment of microscopic colitis. Gastroenterology, 1998. 114(1): p. 29-36.

Sinensetin | Zomepirac (sodium salt) | Flurbiprofen | Limaprost | MF63 | Benzindamine Hydrochloride | HPGDS inhibitor 1 | hPGDS-IN-1 | Pranoprofen | Suprofen | PGS-IN-1

MOLECULAR FORMULA :

C7-H5-Bi-O4

MOLECULAR WEIGHT :

362.10

WISWESSER LINE NOTATION :

QR BVO-BI-O

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :

LDLo - Lowest published lethal dose

ROUTE OF EXPOSURE :

Intramuscular

SPECIES OBSERVED :

Human - man

DOSE/DURATION :

60 mg/kg/26W-I

TOXIC EFFECTS :

Kidney, Ureter, Bladder - changes in tubules (including acute renal failure, acute tubular necrosis)

REFERENCE :

AJCPAI American Journal of Clinical Pathology. (Lippincott/Harper, Journal Fulfillment Dept., 2350 Virginia Ave., Hagerstown, MD 21740) V.1- 1931- Volume(issue)/page/year: 14,392,1944

TYPE OF TEST :

TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :

Intramuscular

SPECIES OBSERVED :

Human - woman

DOSE/DURATION :

14480 ug/kg/9D-I

TOXIC EFFECTS :

Musculoskeletal - joints Skin and Appendages - dermatitis, allergic (after systemic exposure) Nutritional and Gross Metabolic - body temperature increase

REFERENCE :

ADSYAF Archives of Dermatology and Syphilology. (Chicago, IL) V.1-62, 1920-50. For publisher information, see ARDEAC. Volume(issue)/page/year: 41,1076,1940

TYPE OF TEST :

TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :

Intramuscular

SPECIES OBSERVED :

Human - man

DOSE/DURATION :

17 mg/kg/5W-I

TOXIC EFFECTS :

Gastrointestinal - other changes

REFERENCE :

AJSGA3 American Journal of Syphilis, Gonorrhea and Venereal Diseases. (St. Louis, MO) V.20-38, 1936-54. Discontinued. Volume(issue)/page/year: 26,84,1942 *** NIOSH STANDARDS DEVELOPMENT AND SURVEILLANCE DATA *** NIOSH OCCUPATIONAL EXPOSURE SURVEY DATA : NOHS - National Occupational Hazard Survey (1974) NOHS Hazard Code - 80378 No. of Facilities: 96 (estimated) No. of Industries: 1 No. of Occupations: 8 No. of Employees: 3666 (estimated) NOES - National Occupational Exposure Survey (1983) NOES Hazard Code - 80378 No. of Facilities: 405 (estimated) No. of Industries: 2 No. of Occupations: 6 No. of Employees: 4036 (estimated) No. of Female Employees: 2022 (estimated)